Publication at Faculty of Medicine in Hradec Králové |
2016
Abstract
The introduction of "new drugs" in the treatment of multiple myeloma (MM) significantly improved the prognosis of patients, especially those who can not undergo high-dose chemotherapy. One of the representatives of the new generation is carfilzomib.
It is a selective proteasome inhibitor whose use is indicated for patients with relapsed or refractory disease. In this case, it is clearly one of the most effective drugs, which was still in MM patients tested.
The aim of this article is to familiarize readers with the profile of this drug, both its pharmacological properties, and also past experience gained in its use